

Special Issue

Antimycobacterial Agents: New Advances in Combating Drug-Resistant Tuberculosis

Message from the Guest Editor

Despite the medical and social interventions observed for over a century, tuberculosis (TB)—caused by mycobacterium tuberculosis (MTB)—remains a formidable global health challenge. The absence of an effective vaccine against tuberculosis necessitated the broad administration of antibiotics over the past few decades, which, almost inevitably, has hastened the rise in and spread of drug-resistant (DR) and multi-drug-resistant (MDR) Mtb strains globally. In light of this, I am thrilled to invite contributions to our Special Issue titled “Antimycobacterial Agents: Combating Drug-Resistant Tuberculosis” in *Pharmaceutics*. While contributions can be diverse, potential topics might include the following: New chemical or biological antimicrobial methods, such as phase- or host-directed therapy. Insights into the molecular mechanisms and clinical diagnosis of TB drug resistance. Technological breakthroughs in studying the interaction between drugs and bacteria. I eagerly await the opportunity to collaborate and spotlight your significant scientific discoveries.

Guest Editor

Dr. Junhao Zhu

CAS Key Laboratory of Pathogenic Microbiology and Immunology
Institute of Microbiology Chinese Academy of Sciences, Beijing, China

Deadline for manuscript submissions

closed (25 October 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/203784

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)